OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press69610.17650/1818-8346-2008-0-1-2-63-69QUALITY OF LIFE AND FOLLOW-UPКАЧЕСТВО ЖИЗНИ И ДИСПАНСЕРНОЕ НАБЛЮДЕНИЕ ОНКОГЕМАТОЛОГИЧЕСКИХ БОЛЬНЫХObservation of oncohematologic patients by general pediatriciansДиспансерное наблюдение детей и подростков с онкологическими заболеваниями педиатром общей практикиVarfolomeyevaS. R.ВарфоломееваС. Р.
Russian Federation

Moscow

Balashikha

Москва

Балашиха

KachanovD. Yu.КачановД. Ю.
Russian Federation

Moscow

Balashikha

Москва

Балашиха

ShneyderM. M.ШнейдерМ. М.
Russian Federation

Moscow

Москва

DobrenkovK. V.ДобреньковК. В.
Russian Federation

Moscow

Москва

ShamanskayaT. V.ШаманскаяТ. В.
Russian Federation

Moscow

Balashikha

Москва

Балашиха

SamochatovaYe. V.СамочатоваЕ. В.
Russian Federation

Moscow

Москва

RumyantzevA. G.РумянцевА. Г.
Russian Federation

Moscow

Москва

Federal State Enterprise «Federal Research Clinical Center of Pediatric Hematology, Oncology and Immunology of Russian Public HealthФГУ ФНКЦ ДГОИ РосздраваMoscow Regional Oncologic DispensaryМосковский областной онкологический диспансерFederal State Enterprise «Federal Research Clinical Center of Pediatric Hematology, Oncology and Immunology of Russian Public HealthФГУ ФНКЦ ДГОИ Росздрава230520081-2636923112022231120222008https://oncohematology.abvpress.ru/ongm/article/view/696

For past decades there have been substantial changes in the therapy of oncohematologic diseases in children. Today, the treatment of this subset of patients is impossible without close cooperation between pediatric oncology/hematology professionals and general pediatricians. Authors underline the following critical steps in the management of oncohematologic patients necessarily requiring participation of general pediatricians: early diagnosis of malignancies, management of patients during their anti-tumor treatment, observation of patients in complete remissions after effective anti-tumor treatment, management of patents receiving palliative care, organization of hospices. Issues regarding prophylaxis and treatment of infectious complications in oncohematologic patients, use of growth factors, substitutive treatment with blood components and vaccination are reviewed.

В течение последних двух десятилетий в России произошли существенные изменения в терапии онкогематологических заболеваний у детей. На современном этапе терапия данной группы пациентов невозможна без взаимодействия врачей-детских гематологов/онкологов и врачей педиатров общей сети. В данной статье авторы выделяют следующие критические этапы, в которых участие врачей-педиатров общей сети/врачей общей практики является обязательным: ранняя диагностика злокачественных заболеваний; курация пациентов на этапах противоопухолевой терапии; ведение пациентов, находящихся в длительной ремиссии, по окончании противоопухолевого лечения; курация пациентов, находящихся на этапе паллиативной помощи; организация хосписа. Рассмотрены вопросы, касающиеся профилактики и лечения инфекционных осложнений у онкогематологических больных, использования ростовых факторов, заместительной терапии компонентами крови, вакцинации.

childrenmalignanciespediatricianдетизлокачественные опухоливрач-педиатр1. Dang-Tan T., Franco E.L. Diagnosis delays in childhood cancer: a review. Cancer 2007;110(4):703—13.Dang-Tan T., Franco E.L. Diagnosis delays in childhood cancer: a review. Cancer 2007;110(4):703—13.2. Fajardo-GutiОrrez A., Sandoval-Mex A.M., MejТa-ArangurО J.M. et al. Clinical and social factors that affect the time to diagnosis of Mexican children with cancer. Med Pediatr Oncol 2002;39(1):25—31.Fajardo-GutiОrrez A., Sandoval-Mex A.M., MejТa-ArangurО J.M. et al. Clinical and social factors that affect the time to diagnosis of Mexican children with cancer. Med Pediatr Oncol 2002;39(1):25—31.3. Haimi M., Peretz Nahum M., Ben Arush M.W. Delay in diagnosis of children with cancer: a retrospective study of 315 children. Pediatr Hematol Oncol 2004;21(1):37—48.Haimi M., Peretz Nahum M., Ben Arush M.W. Delay in diagnosis of children with cancer: a retrospective study of 315 children. Pediatr Hematol Oncol 2004;21(1):37—48.4. Ross J.A., Spector L.G., Robison L.L., Olshan A.F. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer 2005;44(1):8—12.Ross J.A., Spector L.G., Robison L.L., Olshan A.F. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer 2005;44(1):8—12.5. Agha M.M., Williams J.I., Marrett L. et al. Congenital abnormalities and childhood cancer. Cancer 2005;103(9):1939—48.Agha M.M., Williams J.I., Marrett L. et al. Congenital abnormalities and childhood cancer. Cancer 2005;103(9):1939—48.6. Cabral D.A., Tucker L.B. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999;134(1):53—57.Cabral D.A., Tucker L.B. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999;134(1):53—57.7. Forgie S.E., Robinson J.L. Pediatric malignancies presenting as a possible infectious disease. BMC Infect Dis 2007;7:44.Forgie S.E., Robinson J.L. Pediatric malignancies presenting as a possible infectious disease. BMC Infect Dis 2007;7:44.8. Duzova A., Cetin M., Gümrük F., Yetgin S. Acute tumour lysis syndrome following a single-dose corticosteroid in children with acute lymphoblastic leukaemia. Eur J Haematol 2001;66(6):404—7.Duzova A., Cetin M., Gümrük F., Yetgin S. Acute tumour lysis syndrome following a single-dose corticosteroid in children with acute lymphoblastic leukaemia. Eur J Haematol 2001;66(6):404—7.9. Golden E., Beach B., Hastings C. The pediatrician and medical care of the child with cancer. Pediatr Clin North Am 2002;49(6):1319—38.Golden E., Beach B., Hastings C. The pediatrician and medical care of the child with cancer. Pediatr Clin North Am 2002;49(6):1319—38.10. Koh A.Y., Pizzo P.A. Fever and granulocytopenia. In S.S. Long, L.K. Pickering, C.G. Prober, eds. Principles and Practice of Pediatric Infectious Diseases, 2nd ed. Churchill Livingstone, 2003.Koh A.Y., Pizzo P.A. Fever and granulocytopenia. In S.S. Long, L.K. Pickering, C.G. Prober, eds. Principles and Practice of Pediatric Infectious Diseases, 2nd ed. Churchill Livingstone, 2003.11. Link H., Böhme A., Cornely O.A. et al. Antimicrobial therapy of unexplained fever in neutropenic patientsguidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82 (Suppl 2):105—17.Link H., Böhme A., Cornely O.A. et al. Antimicrobial therapy of unexplained fever in neutropenic patientsguidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82 (Suppl 2):105—17.12. Secmeer G., Devrim I., Kara A. et al. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol 2007;29(2):107—11.Secmeer G., Devrim I., Kara A. et al. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol 2007;29(2):107—11.13. Fleischhack G., Kambeck I., Cipic D. et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000;111(4):1093—102.Fleischhack G., Kambeck I., Cipic D. et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000;111(4):1093—102.14. Enright A.M., Prober C. Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections. Herpes 2003;10(2):32—7.Enright A.M., Prober C. Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections. Herpes 2003;10(2):32—7.15. Mantadakis E., Anagnostatou N., Danilatou V. et al. Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review. J Pediatr Hematol Oncol 2005;27(10):551—3.Mantadakis E., Anagnostatou N., Danilatou V. et al. Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review. J Pediatr Hematol Oncol 2005;27(10):551—3.16. Arvin A.M. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002;13(1):12—21.Arvin A.M. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002;13(1):12—21.17. Hughes W.T., Rivera G.K., Schell M.J. et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316(26):1627—32.Hughes W.T., Rivera G.K., Schell M.J. et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316(26):1627—32.18. Lindemulder S., Albano E. Successful intermittent prophylaxis with trimethoprim/ sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007;120(1):e47—е51.Lindemulder S., Albano E. Successful intermittent prophylaxis with trimethoprim/ sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007;120(1):e47—е51.19. Gibson B.E., Todd A., Roberts I. et al; British Commitee for Standards in Haematology Transfusion Task Force: Writing group. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124(4):433—53.Gibson B.E., Todd A., Roberts I. et al; British Commitee for Standards in Haematology Transfusion Task Force: Writing group. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124(4):433—53.20. Levine J.E., Boxer L.A. Clinical applications of hematopoietic growth factors in pediatric oncology. Curr Opin Hematol 2002;9(3):222—7.Levine J.E., Boxer L.A. Clinical applications of hematopoietic growth factors in pediatric oncology. Curr Opin Hematol 2002;9(3):222—7.21. Wittman B., Horan J., Lyman G.H. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev 2006;32(4):289—303.Wittman B., Horan J., Lyman G.H. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev 2006;32(4):289—303.22. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187—205.Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187—205.23. Schnell F.M. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003;8(2):187—98.Schnell F.M. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003;8(2):187—98.24. Berger A.M., Clark-Snow R.A. Chemotherapy-related nausea and vomiting. In A.M. Berger, J.L. Shuster, J.H. Von Roenn, eds. Principles & Practice of Palliative Care & Supportive Oncology. Lippincott Williams and Wilkins, 2006.Berger A.M., Clark-Snow R.A. Chemotherapy-related nausea and vomiting. In A.M. Berger, J.L. Shuster, J.H. Von Roenn, eds. Principles & Practice of Palliative Care & Supportive Oncology. Lippincott Williams and Wilkins, 2006.25. Ettinger D.S., Bierman P.J., Bradbury B. et al. National comprehensive Cancer Network (NCCN). Antiemesis. J Natl Compr Canc Netw 2007;5(1):12—33.Ettinger D.S., Bierman P.J., Bradbury B. et al. National comprehensive Cancer Network (NCCN). Antiemesis. J Natl Compr Canc Netw 2007;5(1):12—33.26. Roila F., Feyer P., Maranzano E., Olver I. et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 2005;13(2):129—31.Roila F., Feyer P., Maranzano E., Olver I. et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 2005;13(2):129—31.27. Köseoglu V., KürekНi A.E., Sarici U. et al. Comparison of the efficacy and sideeffects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 1998;157(10):806—10.Köseoglu V., KürekНi A.E., Sarici U. et al. Comparison of the efficacy and sideeffects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 1998;157(10):806—10.28. Allen U.D. Immunizations for children with cancer. Pediatr Blood Cancer 2007;49 (Suppl 7):1102—8.Allen U.D. Immunizations for children with cancer. Pediatr Blood Cancer 2007;49 (Suppl 7):1102—8.29. Nilsson A., De Milito A., Engström P. et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109(6):e91.Nilsson A., De Milito A., Engström P. et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109(6):e91.30. Price V.E., Dutta S., Blanchette V.S. et al. The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer 2006;46(5):597—603.Price V.E., Dutta S., Blanchette V.S. et al. The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer 2006;46(5):597—603.31. Martinson I.M., Amrstrong G.D., Geis D.P. et al. Home care for children dying of cancer. Pediatrics 1978;62(1):106—13.Martinson I.M., Amrstrong G.D., Geis D.P. et al. Home care for children dying of cancer. Pediatrics 1978;62(1):106—13.32. Vickers J.L., Carlisle C. Choices and control: parental experiences in pediatric terminal home care. J Pediatr Oncol Nurs 2000;17(1):12—21.Vickers J.L., Carlisle C. Choices and control: parental experiences in pediatric terminal home care. J Pediatr Oncol Nurs 2000;17(1):12—21.33. Davies B., Deveau E., deVeber B. et al. Experiences of mothers in five countries whose child died of cancer. Cancer Nurs 1998;21(5):301—11.Davies B., Deveau E., deVeber B. et al. Experiences of mothers in five countries whose child died of cancer. Cancer Nurs 1998;21(5):301—11.34. Beardsmore S., Fitzmaurice N. Palliative care in paediatric oncology. Eur J Cancer 2002;38(14):1900—7.Beardsmore S., Fitzmaurice N. Palliative care in paediatric oncology. Eur J Cancer 2002;38(14):1900—7.35. Robison L.L., Green D.M., Hudson M. et al. Long-term outcomes of adult survivors of childhood cancer. Cancer 2005;104 (Suppl 11):2557—64.Robison L.L., Green D.M., Hudson M. et al. Long-term outcomes of adult survivors of childhood cancer. Cancer 2005;104 (Suppl 11):2557—64.36. Mertens A., Yasui Y., Neglia J.P. et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19(13):3163—72.Mertens A., Yasui Y., Neglia J.P. et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19(13):3163—72.37. Neglia J.P., Friedman D.L., Yasui Y. et al. Second malignant neoplasms in fiveyear survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2001;93(8):618—29.Neglia J.P., Friedman D.L., Yasui Y. et al. Second malignant neoplasms in fiveyear survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2001;93(8):618—29.38. Olsen J.H., Garwicz S., Hertz H. et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 1993;307(6911):1030—6.Olsen J.H., Garwicz S., Hertz H. et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 1993;307(6911):1030—6.39. Kurt B.A., Armstrong G.T., Cash D.K. et al. Primary care management of the childhood cancer survivor. J Pediatr 2008;152(4):458—66.Kurt B.A., Armstrong G.T., Cash D.K. et al. Primary care management of the childhood cancer survivor. J Pediatr 2008;152(4):458—66.